These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18607107)

  • 21. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis.
    Prescrire Int; 2009 Dec; 18(104):252. PubMed ID: 20025092
    [No Abstract]   [Full Text] [Related]  

  • 23. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
    Wiendl H; Hohlfeld R
    Neurology; 2009 Mar; 72(11):1008-15. PubMed ID: 19289741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
    Pula JH; Javed A
    Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Ziemssen T; Schrempf W
    Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Livedo-like dermatitis (Nicolau's syndrome) after injection of Copolymer-1 (Glatiramer acetate)].
    Gaudez C; Regnier S; Aractingi S; Heinzlef O
    Rev Neurol (Paris); 2003 May; 159(5 Pt 1):571-3. PubMed ID: 12773903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
    Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
    Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous adverse events related to glatiramer acetate injection (copolymer-1, Copaxone).
    Kluger N; Thouvenot E; Camu W; Guillot B
    J Eur Acad Dermatol Venereol; 2009 Nov; 23(11):1332-3. PubMed ID: 19470043
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of glatiramer acetate (Copaxone) given orally in human patients: interleukin-10 production during a phase 1 trial.
    de Seze J; Edan G; Labalette M; Dessaint JP; Vermersch P
    Ann Neurol; 2000 May; 47(5):686. PubMed ID: 10805349
    [No Abstract]   [Full Text] [Related]  

  • 31. Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases.
    Kümpfel T; Hoffmann LA; Pellkofer H; Pöllmann W; Feneberg W; Hohlfeld R; Lohse P
    Neurology; 2008 Nov; 71(22):1812-20. PubMed ID: 19029521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Crohn's disease after administration of oral contraceptives. Report of a case (author's transl)].
    Bourdais JP; Delavierre P; Vayre P; Hureau J; Letailleur M
    Arch Fr Mal App Dig; 1976 Mar; 65(2):155-60. PubMed ID: 949216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Schrempf W; Ziemssen T
    Autoimmun Rev; 2007 Aug; 6(7):469-75. PubMed ID: 17643935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort.
    Weersma RK; Stokkers PC; van Bodegraven AA; van Hogezand RA; Verspaget HW; de Jong DJ; van der Woude CJ; Oldenburg B; Linskens RK; Festen EA; van der Steege G; Hommes DW; Crusius JB; Wijmenga C; Nolte IM; Dijkstra G;
    Gut; 2009 Mar; 58(3):388-95. PubMed ID: 18824555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.
    Fromont A; De Seze J; Fleury MC; Maillefert JF; Moreau T
    Cytokine; 2009 Feb; 45(2):55-7. PubMed ID: 19109035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH; Bressler B
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.
    Miller A; Shapiro S; Gershtein R; Kinarty A; Rawashdeh H; Honigman S; Lahat N
    J Neuroimmunol; 1998 Dec; 92(1-2):113-21. PubMed ID: 9916886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A place of first-line drugs in treatment of multiple sclerosis].
    Kasatkin DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):145-151. PubMed ID: 28635741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies.
    Antel JP; Miron VE
    Clin Neurol Neurosurg; 2008 Nov; 110(9):951-7. PubMed ID: 18502570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glatiramer acetate: a novel therapeutic approach in Crohn's disease?
    Neesse A; Michl P; Kunsch S; Gress TM; Steinkamp M
    Inflamm Bowel Dis; 2009 Jan; 15(1):156-7. PubMed ID: 18626969
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.